|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 23, 2024 ) InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Radiopharmaceuticals Market Size, Share & Trends Analysis Report By Type (Diagnostic Nuclear Medicine (SPECT Radiopharmaceuticals, PET Radiopharmaceuticals), Therapeutic Nuclear Medicine (Alpha Emitters, Beta Emitters), Brachytherapy Isotopes. By Application (Diagnostic Applications (SPECT Applications, PET Applications), Therapeutic Applications) - Market Outlook and Industry Analysis 2031"
Download Free Demo Report: https://www.insightaceanalytic.com/request-sample/2290
Radiopharmaceuticals refers to biologics production in plant systems to reduce the cost of microbial systems. Molecular farming is an innovative method for producing molecular medicines, including plasma proteins, enzymes, growth factors, vaccinations, and recombinant antibodies. These medicines have widely accepted medicinal uses at a molecular level. The approach has the potential to change the pharmaceutical industry by providing highly efficient and cost-effective treatments to all segments of the population. Plant-based protein expression offers practical, secure, efficient, and cost-effective advantages.
Radiopharmaceuticals has the potential to offer a new platform for the development and delivery of vaccines and therapeutics for infectious diseases, particularly in low-resource environments. It can also contribute to improving human health and well-being by generating proteins that can regulate various physiological functions, including growth, metabolism, reproduction, and immunity. By encouraging innovation, collaboration, and diversification, Radiopharmaceuticals can also generate novel opportunities for the biotechnology sector and the entrepreneurial landscape.
It can potentially facilitate the creation of innovative products and services that can directly address unmet medical requirements and market demands. The global molecular pharmaceutical industry will rise rapidly due to the expansion of studies into producing pharmaceuticals from plants and products. The sudden demand for precision medicine and its production from natural and organic sources will contribute to the market's growth during the next five years.
List of Prominent Players in the Radiopharmaceuticals Market:
GE HealthCare
Cardinal Health
Curium
Bayer AG
Lantheus Holdings, Inc.
Bracco Imaging S.p.A.
PharmaLogic Holdings Corp.
Eczacibasi-Monrol Nuclear Products
NTP Radioisotopes SOC Ltd
Nordion Inc.
Novartis (Advanced Accelerator Application)
NorthStar Medical Radioisotopes
Eckert & Ziegler
Isotope JSC
Siemens Healthineers
Jubilant DraxImage,Inc.
Telix Pharmaceuticals Limited
Mallinckrodt Pharmaceuticals
Bracco
IBA Worldwide
Other Prominent Players
Market Dynamics:
Drivers-
The radiopharmaceuticals market is experiencing robust growth, driven by factors such as the prevalence of chronic conditions among older adultsnearly 95% of whom have at least one chronic condition and 80% have two or more, according to NCOA research. Technological advancements in radiopharmaceutical production, including novel radiotracers and targeted therapies, are further propelling market expansion. Regulatory approvals from bodies like the FDA and EMA, alongside increasing healthcare expenditure in developed economies, support the development and adoption of these advanced therapies. Additionally, the growing application of radiopharmaceuticals across diverse medical fields and rising awareness among healthcare professionals and patients are key contributors to market growth.
Challenges:
The radiopharmaceutical industry encounters challenges such as stringent regulatory hurdles delaying product innovation, complex production requirements needing specialized facilities and trained personnel, short shelf-life necessitating precise logistics, strict radiation safety protocols, and high costs impacting accessibility, especially in developing regions.
Regional Trends:
North America, particularly the United States, boasts a well-established nuclear medicine infrastructure with advanced SPECT and PET imaging technologies, alongside a network of radiopharmacies capable of producing and administering radiopharmaceuticals. The region benefits from a favorable regulatory environment set by the FDA, which provides clear guidelines and efficient approval processes for new radiopharmaceutical products, facilitating their development and commercialization. Key market players like Lantheus Medical Imaging, Bayer, and GE Healthcare have substantial operations in North America, leveraging robust research and development activities supported by numerous academic institutions and government agencies. The availability of significant funding and investments further propels innovation in radiopharmaceutical technologies, meeting the rising demand for advanced diagnostic and therapeutic applications driven by the increasing prevalence of chronic diseases across the region.
Curious about this latest version of the report? @ https://www.insightaceanalytic.com/enquiry-before-buying/2290
Recent Developments:
In July 2024, Nusano Inc. and PharmaLogic Holdings Corp. have entered into a supply agreement to enhance the availability of medical radioisotopes. This partnership aims to ensure a more efficient and reliable supply of critical radioisotopes for pharmaceutical products manufactured across PharmaLogic's network of facilities.
In July 2024, Curium, a nuclear medicine firm, filed a new drug application (NDA) for its lutetium-177 (Lu-177) DOTATATE radiopharmaceutical. This submission aims to secure approval for treating somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETS).
In March 2022, Blue Earth Therapeutics holds exclusive global rights to use radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) technology for both diagnostic imaging and treatment of prostate cancer. This innovative theranostic technology combines diagnostic capabilities with therapeutic applications for enhanced patient care.
Segmentation of Radiopharmaceuticals Market-
By Type:
Diagnostic Nuclear Medicine
o SPECT Radiopharmaceuticals
Tc-99m
I-123
Tl-201
Ga-67
Other SPECT Isotopes
o PET Radiopharmaceuticals
F-18
Rb-82
Other PET Isotopes
Therapeutic Nuclear Medicine
o Alpha Emitters
Ra-223
o Beta Emitters
I-131
Y-90
Sm-153
Lu-177
Re-186
Other Beta Emitters
o Brachytherapy Isotopes
I-125
Ir-192
Pd-103
Cs-131
Other Brachytherapy Isotopes
By Application:
Diagnostic Applications
o SPECT Applications
Cardiology
Bone Scans
Thyroid Applications
Pulmonary Scans
Other SPECT Applications
o PET Applications
Oncology
Cardiology
Neurology
Other PET Applications
Therapeutic Applications
o Thyroid Indications
o Bone Metastasis
o Lymphoma
o Endocrine Tumors
o Other Indications
By Region-
North America-
The US
Canada
Mexico
Europe-
Germany
The UK
France
Italy
Spain
Rest of Europe
Asia-Pacific-
China
Japan
India
South Korea
South East Asia
Rest of Asia Pacific
Latin America-
Brazil
Argentina
Rest of Latin America
Middle East & Africa-
GCC Countries
South Africa
Rest of Middle East and Africa
For More Customization @ https://www.insightaceanalytic.com/customisation/2290
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Insight Ace Analytics
Diana Dsouza
+8884144123
diana.dsouza@insightaceanalytics.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
